Hello and thanks for joining this special edition of

thoughts in the market.

From London I'm Andrew Sheets, chief cross-asset

strategist from Morgan Stanley.

And from New York, I'm Matthew Harrison, managing director and equity research analyst

covering biotechnology.

Today we'll be talking about the road

to a coronavirus vaccine and how those efforts

could help shape the market outlook over the next year.

It's Thursday, June 4th at 2 PM in London.

Matt, I think a good place to start.

Could you talk about some of the different approaches

to a vaccine that are being taken

and how you're thinking about that.

Sure, so there are a wide variety of approaches to make vaccines.

Some are very new technologies using genetic materials to elicit an immune response and some are older technologies

where you take the live virus itself and you do what's called attenuate it or try and reduce the infectiousness of the virus.

Those techniques are being broadly used among a wide variety of companies.

And there are about 110 approaches that various people have suggested of which eight

are currently in clinical development.

Matt, what's your timeline for a vaccine and I guess what are the milestones that you'll be watching

for to know if we are or aren't making progress on that timeline?

...